Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trialJane C. Burns, Nichole Samuy, Emily Ansusinha et al.|The Lancet Child & Adolescent Health|2021Cited by 113
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Sonia Jain et al.|Contemporary Clinical Trials|2019Cited by 25
Travel-Related Infections in ChildrenThomas G. Fox, John C. Christenson, John J. Manaloor|Pediatric Clinics of North America|2013Cited by 25
Photo Quiz: Diarrhea and Fever in a Child Returning from AfricaRyan F. Relich, Thomas G. Fox, John J. Manaloor|Journal of Clinical Microbiology|2015Cited by 2
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Sonia Jain et al.|Author eBooks|2019Cited by 1